Preclinical pharmacokinetics and metabolism of MNP001, a piperidine analog of 3-carbamyl compounds

Biopharmaceutics and Drug Disposition

Volumn 32, Issue 1, 2011, Pages 25-37

  Xia, Binfeng ^a   Wang, Desuo ^b   Fox, Laura M ^c  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^c PRESBYTERIAN COLLEGE   (United States)

Author keywords

bioavailability; metabolism; MNP001; pharmacokinetics; plasma protein binding

Indexed keywords

CYTOCHROME P450; MNP 001; PIPERIDINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; INTESTINE FLUID; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSOME; NONHUMAN; PHASE PARTITIONING; PHENOTYPE; PHYSICAL CHEMISTRY; PLASMA CELL; PLASMA PROTEIN BINDING; RAT; STOMACH JUICE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MICROSOMES, LIVER; PIPERIDINES; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78650410504     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.736     Document Type: Article

References (28)

1. Wang T, Fox LM, Wang D,. Validation of HPLC analysis method of a novel antihypertensive agent MS23 in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 803: 13-17. DOI: 10.1016/j.jchromb.2005.10.009.
2. Xia B, Wang T, Fox LM, Wang D,. HPLC/MS/MS analysis of 3-carbamyl-4-methylpyrrole analog MNP001, a highly potent antihypertensive agent, in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 1867-1872. DOI: 10.1016/j.jchromb.2009.05.011.
3. Colledge M, Scott JD,. AKAPs: from structure to function. Trends Cell Biol 1999; 9: 216-221. DOI: 10.1016/S0962-8924(99)01558-5.
4. Pauvert O, Salvail D, Rousseau E, Lugnier C, Marthan R, Savineau JP,. Characterisation of cyclic nucleotide phosphodiesterase isoforms in the media layer of the main pulmonary artery. Biochem Pharmacol 2002; 63: 1763-1772. DOI: 10.1016/S0006-2952(02)00919-X.
5. 1 receptor-mediated activation of the locus coeruleus revealed by SR 142801. Synapse 2002; 43: 62-69. DOI: 10.1002/syn.10021.
6. Robichaud A, Tattersall FD, Choudhury I, Rodger IW,. Emesis induced by inhibitors of type IV cyclic nucleotide phosphodiesterase (PDE IV) in the ferret. Neuropharmacology 1999; 38: 289-297. DOI: 10.1016/S0028-3908(98)00190-7.
7. Wang D, Wang T,. Novel approaches to using PDE4 inhibitors for antihypertensive therapy. Curr Opin Investig Drugs 2005; 6: 283-288.
8. Wang T, Wang D,. High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma. J Pharm Biomed Analysis 2006; 42: 607-612. DOI: 10.1016/j.jpba.2006.05.010.
9. Ette E, Williams P,. Population pharmacokinetics II: estimation methods. Ann Pharmacother 2004; 38: 1907-1915.
10. Newton DJ, Wang RW, Lu AY,. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-158.
11. Elsherbiny ME, El-Kadi AO, Brocks DR,. The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharm Sci 2008; 11: 147-159.
12. Houston JB,. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469-1479.
13. Stephen J, Stephen T., Solubility of Inorganic and Organic Compounds, Vol 1, Binary Systems, Part 1, Macmillan: New York, 1963.
14. The Millipore website. [15 August 2009 ].
15. Wright JD, Boudinot FD, Ujhelyi MR,. Measurement and analysis of unbound drug concentration. Clin Pharmacokinet 1996; 30: 445-462.
16. Whitlam JB, Brown KF,. Ultrafiltration in serum protein binding determinations. J Pharm Sci 1981; 70: 146-150.
17. Crowe A, Bruelisauer A, Duerr L, Guntz P, Lemaire M,. Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos 1999; 27: 627-632.
18. Poet TS, Wu H, Kousba AA, Timchalk C,. In vitro rat hepatic and intestinal metabolism of the organophosphate pesticides chlorpyrifos and diazinon. Toxicol Sci 2003; 72: 193-200. DOI: 10.1093/toxsci/kfg035 (Pubitemid 36443097)
19. Ireson CR, Jones DJ, Orr S, et al., Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105-111.
20. Zhang Y, Benet LZ,. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40: 159-168.
21. Osborne R, Thompson P, Joel S, Trew D, Patel N, Slevin M,. The analgesic activity of morphine 6-glucuronide. Br J Clin Pharmacol 1992; 34: 130-138.
22. Flower RJ, Moncada S, Vane JR,. Analgesic-antipyretics and anti-inflammatory agents: drugs employed in the treatment of gout. In Goodman and Gilman's The Pharmacological Basis of Therapeutics, Gilman AG, Goodman LS, Rall TW, Murad F, (eds). Macmillan Publisher: New York, 1985; 674-715.
23. Baldessarini RJ,. Drugs and the treatment of psychiatric disorders. In Goodman and Gilman's the Pharmacological Basis of Therapeutics, Gilman AG, Goodman LS, Rall TW, Murad F, (eds). Macmillan Publisher: New York, 1990; 383-435.
24. Peris-Ribera JE, Torres-Molina F, Garcia-Carbonell MC, Aristorena JC, Granero L,. General treatment of the enterohepatic recirculation of drugs and its influence on the area under the plasma level curves, bioavailability, and clearance. Pharm Res 1992; 9: 1306-1313.
25. Tasker RA, Nakatsu K,. Factors affecting ultrafiltration-assessed values for drug binding. Clin Chem 1982; 28: 1244-1246.
26. Lee KJ, Mower R, Hollenbeck T, et al,. Modulation of nonspecific binding in ultrafiltration protein binding studies. Pharm Res 2003; 20: 1015-1021. DOI: 10.1023/A:1024406221962.
27. Kwon Y,. Blood vs plasma clearance. In Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists. Springer-Verlag Inc.: New York, 2001, 100-102.
28. Kotegawa T, Laurijssens BE, Von Moltke LL, et al,. In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 2002; 302: 1228-1237. DOI: 10.1124/jpet.102. 035972 (Pubitemid 34920247)